Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Julia Ioana"'
Autor:
Osamah A Hakami, Julia Ioana, Shahzad Ahmad, Tommy Kyaw Tun, Seamus Sreenan, John H McDermott
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2019)
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved fo
Externí odkaz:
https://doaj.org/article/f1ddf987aa19450fa4077f8c717dd969
Autor:
Faul, Martyna Sanecka, Modar Youssef, Mohammad Abdulsalam, Syed F. Raza, Abdul Qadeer, Julia Ioana, Alya Aldoresi, Syed I. Shah, Abdul Al Lawati, Joseph Feely, William P. Tormey, Eoghan O’Neill, Liam J. Cormican, Eoin P. Judge, Daniel M. A. McCartney, John L.
Publikováno v:
Nutrients; Volume 15; Issue 13; Pages: 2976
SARS-CoV-2 vaccination promises to improve outcomes for patients with COVID-19 pneumonia (most notably those with advanced age and at high risk for severe disease). Here, we examine serum 25-Hydroxyvitamin D (25(OH)D) status and outcomes in both old
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::15f5a0ac555c7ca2ed4e8329de34034e
Vitamin D Status and Mortality from SARS CoV-2: A Prospective Study of Unvaccinated Caucasian Adults
Autor:
Robert Barrett, Modar Youssef, Irfan Shah, Julia Ioana, Abdullah Al Lawati, Abdullah Bukhari, Suzanne Hegarty, Liam J. Cormican, Eoin Judge, Conor M. Burke, Catriona Cody, Joseph Feely, Katrina Hutchinson, William Tormey, Eoghan O’ Neill, Aoife O’ Shea, Meabh Connolly, Daniel M. A. McCartney, John L. Faul
Publikováno v:
Nutrients; Volume 14; Issue 16; Pages: 3252
Articles
Articles
COVID-19 and a low vitamin D state share common risk factors, which might explain why vitamin D deficiency has been linked with higher COVID-19 mortality. Moreover, measures of serum vitamin D may become lower during systemic inflammatory responses,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bfa09fa527217cc4d67cabb636be1d
https://pubmed.ncbi.nlm.nih.gov/36014757
https://pubmed.ncbi.nlm.nih.gov/36014757
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2019)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2019)
Summary Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96c34adcd78ab02f2761e0febd82800d
http://europepmc.org/articles/PMC6432978
http://europepmc.org/articles/PMC6432978